Abcellera Biologics INC Form 4 insider transactions

Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc., purchased 37,200 shares of common stock on August 14, 2026 for $10.32 per share.

Michael R Hayden, a Director of AbCellera Biologics Inc., purchased 46,387 shares of common stock on August 12, 2026 for $10.37 per share.

Michael R Hayden, a Director of AbCellera Biologics Inc., reported a transaction in 50,000 shares of common stock on August 11, 2026.

Director Lynn Seely of AbCellera Biologics Inc. acquired stock options, with vesting scheduled over three years.

Victor Sandor, a Director at AbCellera Biologics Inc., has acquired stock options as part of his compensation, with vesting over three years.

Director Michael R. Hayden was granted 111,701 stock options in AbCellera Biologics Inc. as part of standard compensation.

Director Stephen Quake was granted options to purchase 111,701 common shares of AbCellera Biologics Inc. on June 11, 2026.

Director John S. Montalbano was granted 111,701 stock options in AbCellera Biologics Inc. as part of an equity incentive.

Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc., reported a transaction involving the acquisition of 250,000 common shares.

AbCellera Biologics Inc. Director John Montalbano reported transactions involving company common shares, including acquisitions and dispositions.

Thermopylae Holdings, a 10% owner and director of AbCellera Biologics, acquired 38,000 common shares at a weighted-average price of $3.44 per share.

Thermopylae Holdings, a 10% owner and director of AbCellera Biologics, acquired 177,457 common shares for approximately $580,000.

AbCellera Biologics Inc.'s Chief Financial Officer, Andrew Booth, acquired 42,600 common shares at $3.42 per share.

AbCellera Biologics Inc. Chief Financial Officer Andrew Booth was granted 808,898 share options with an exercise price of $3.42, vesting over four years.

AbCellera Biologics Inc.'s CEO, Carl L. G. Hansen, was granted 2,106,505 share options with an exercise price of $3.42, vesting over four years.

AbCellera Biologics' Chief Legal Officer, Tryn Stimart, was granted 539,265 share options with an exercise price of $3.42.

AbCellera Biologics' Chief Technology Officer, Veronique Lecault, was granted 539,265 stock options with a $3.42 exercise price, vesting over four years.

AbCellera Biologics Inc. Director Stephen Quake was granted 194,932 share options with an exercise price of $3.47, vesting over three years.

Thermopylae Holdings Ltd., a 10% owner and director of AbCellera Biologics Inc., reported a charitable donation of 225,000 common shares.

AbCellera Biologics Director John S. Montalbano acquired 50,000 common shares at $3.5692 each in a pre-planned transaction, increasing his direct beneficial ownership.

AbCellera Biologics Inc. Director Michael R. Hayden was granted 238,864 share options with an exercise price of $3.15, vesting at the 2026 Annual General Meeting.

AbCellera Biologics Inc. Director and 10% Owner John S. Montalbano has acquired 238,864 share options with an exercise price of $3.15, set to vest at the 2026 Annual General Meeting.

AbCellera Biologics Inc. Director Andrew Lo was granted 238,864 share options with an exercise price of $3.15, vesting at the 2026 Annual General Meeting.

Thermopylae Holdings Ltd. reports purchasing 343,631 common shares of AbCellera Biologics Inc. at an average price of $2.16 per share, increasing its total holdings to 56,143,640 shares.

Director John S. Montalbano of AbCellera Biologics Inc. reports purchasing 25,000 common shares at $2.3 each.

Director John S. Montalbano of AbCellera Biologics Inc. reports the acquisition of 60,000 common shares at $2.3428 per share on March 6, 2025.

Tryn Stimart, Chief Legal Officer of AbCellera Biologics, has been granted 832,033 share options with a strike price of $2.93, vesting over four years.

Veronique Lecault, Chief Operating Officer of AbCellera Biologics Inc., was granted 832,033 share options on January 1, 2025.

Chief Financial Officer of AbCellera Biologics, Andrew Booth, reports the acquisition of share options.

AbCellera Biologics CEO, Carl L.G. Hansen, was granted 2,730,109 share options on January 1, 2025, which vest over a four-year period.